. 2015 May 29;424:111–119. doi: 10.1016/j.jim.2015.05.009

Table 3.

B cell responses elicited by DC-vaccines in the presence of Advax.

Vaccine^a	Anti-peptide IgM antibodies^b
Vaccine^a	LLO_91–99	GAPDH_1–22
Control	0.156 ± 0.05	0.163 ± 0.04
NV	0.517 ± 0.02	1.021 ± 0.02
DC-GAPDH_1–22	0.712 ± 0.02	2.011 ± 0.05
DC-LLO_91–99	0.583 ± 0.03	1.276 ± 0.02

Vaccine^a	Spleen markers^c
Vaccine^a	CD19⁺	CD4⁺	CD8⁺	CD11c⁺-CD86⁺
Control	19 ± 0.5	7 ± 0.3	8 ± 0.2	0.5 ± 0.02
NV	15 ± 0.5	18 ± 0.6	17 ± 0.5	26 ± 0.8
DC-GAPDH_1–22	15 ± 0.3	26 ± 0.4	28 ± 0.5	70 ± 0.7
DC-LLO_91–99	15 ± 0.2	7 ± 0.2	27 ± 0.3	70 ± 0.6

C57BL/6 (Table) or Balb/c (data not shown) mice were vaccinated in the presence of Advax (50 μg/ml) with DC-GAPDH_1–22 or DC-LLO_91–99 vaccines or non-vaccinated (NV). 7 days post-vaccination, vaccinated and NV mice were infected with 5 × 10³ CFU of LM^WT for 5 days. Control mice were non-vaccinated and non-infected. Next, mice were sacrificed and sera collected and stored at − 80 °C. Spleens were homogenized for further analysis.

Sera from vaccinated, non-vaccinated or control mice were thawed and examined peptide-ELISA as described in Methods section. Reactions were developed with goat anti-mouse IgM and absorbances analysed at 450 nm. Results are the mean of triplicates ± SD.

Cell surface markers were examined in spleens of vaccinated, non-vaccinated or control mice after incubation with different antibodies conjugated with fluorochromes and analyse by FACS. Results corresponded to the mean of the percentages of positive cells ± SD.